TECHWIRE 30
(CIX: WRAL30)  1,025.57  up arrow+2.13  (0.21 %)  Updated: 02:41 PM EST, Feb 10 2016
(NQ: Apple)  94.98  down arrow-0.01  (-0.01 %)  Updated: 02:42 PM EST, Feb 10 2016
(NY: QUINTILES)  58.99  up arrow+2.29  (4.04 %)  Updated: 02:41 PM EST, Feb 10 2016
(OP: BASF SE)  65.02  down arrow-0.02  (-0.04 %)  Updated: 02:41 PM EST, Feb 10 2016
(NQ: BioCryst)  1.86  down arrow-0.03  (-1.59 %)  Updated: 02:40 PM EST, Feb 10 2016
(NQ: BioDelivery)  3.50  down arrow-0.08  (-2.1 %)  Updated: 02:41 PM EST, Feb 10 2016
(NQ: CEMP)  16.95  up arrow+0.46  (2.81 %)  Updated: 02:41 PM EST, Feb 10 2016
(NQ: Cisco)  22.70  up arrow+0.05  (0.21 %)  Updated: 02:42 PM EST, Feb 10 2016
(NQ: Cree)  29.43  up arrow+0.07  (0.24 %)  Updated: 02:41 PM EST, Feb 10 2016
(NQ: DARA)  0.88    (0 %)  Updated: 08:10 PM EST, Dec 04 2015
(NY: EMC)  24.56  up arrow+0.39  (1.6 %)  Updated: 02:42 PM EST, Feb 10 2016
(NQ: Extreme Networks)  2.46  down arrow-0.06  (-2.45 %)  Updated: 02:41 PM EST, Feb 10 2016
(NQ: Facebook)  102.14  up arrow+2.6  (2.61 %)  Updated: 02:42 PM EST, Feb 10 2016
(NY: GLAXOSMITHKLINE)  39.31  down arrow-0.03  (-0.08 %)  Updated: 02:41 PM EST, Feb 10 2016
(NQ: Alphabet)  690.69  up arrow+12.58  (1.86 %)  Updated: 02:42 PM EST, Feb 10 2016
(NY: IBM)  121.47  down arrow-2.6  (-2.1 %)  Updated: 02:41 PM EST, Feb 10 2016
(NY: LH)  105.38  up arrow+2.85  (2.78 %)  Updated: 02:41 PM EST, Feb 10 2016
(OP: Lenovo Group)  16.75  up arrow+0.25  (1.52 %)  Updated: 02:37 PM EST, Feb 10 2016
(NY: MRK)  49.93  up arrow+0.77  (1.57 %)  Updated: 02:41 PM EST, Feb 10 2016
(NQ: Microsoft)  50.07  up arrow+0.79  (1.6 %)  Updated: 02:41 PM EST, Feb 10 2016
(NQ: NetApp)  22.62  up arrow+0.58  (2.61 %)  Updated: 02:42 PM EST, Feb 10 2016
(NY: NOVARTIS AG)  73.38  up arrow+0.76  (1.05 %)  Updated: 02:41 PM EST, Feb 10 2016
(OP: Novozymes A/S)  41.38  up arrow+0.38  (0.92 %)  Updated: 02:37 PM EST, Feb 10 2016
(NY: Pfizer)  29.69  up arrow+0.59  (2.01 %)  Updated: 02:42 PM EST, Feb 10 2016
(NQ: Pozen)  5.94    (0 %)  Updated: 08:10 PM EST, Feb 05 2016
(NY: Red Hat)  64.32  up arrow+2.72  (4.41 %)  Updated: 02:42 PM EST, Feb 10 2016
(NQ: BBRY)  6.66  down arrow-0.06  (-0.89 %)  Updated: 02:42 PM EST, Feb 10 2016
(NQ: Salix)  172.81    (0 %)  Updated: 08:10 PM EDT, Apr 01 2015
(NQ: SQI)  11.99  down arrow-0.06  (-0.5 %)  Updated: 02:40 PM EST, Feb 10 2016

Posts tagged “Biotech & Life Science”

12:24 p.m. today

Virginia-based CRO brings animal research facility to Triad

SoBran BioScience, a 500-employee contract research organization based in Fairfax, Va., will open a new animal research facility this summer in Greensboro, providing a bio-boost for the Triad.

Animal research facility coming to Triad Animal research facility coming to Triad

6:20 a.m. today

Report: SEC investigating former Salix executives

Salix        The former CEO and CFO of Salix Pharmaceuticals, which was sold to Valeant Pharmaceuticals for more than $11 billion a year ago, are being investigated by the SEC, according to the Reuters news service.

1:11 p.m. yesterday

Premium Lock Novozymes reorganizes; changes may create some new jobs

Novozymes Novozymes, a global company focusing on enzyme development and production, is reorganizing. Its North America leader explains what's happening and says there will be some new jobs as a result.

12:07 p.m. yesterday

Premium Lock Durham-based Chimerix reports progress in smallpox vaccine

Bioterror     Chimerix, which has a contract potentially worth more than $400 million in the development of a first vaccine targeting smallpox, reports progress in development of an antiviral. In recent tests, its brincidofovir successfully treated 100 percent of animals infected with rabbitpox.

Updated 7:32 a.m. yesterday

Premium Lock Stampede! A 71% share wipeout for Biocryst after drug trial failure

Talk about a sell-off. Early Monday, Triangle-based Biocryst disclosed news that a drug candidate targeting a rare genetic condition had failed. The news set off an immediate plunge in its share price, triggered a Wall Street downgrade - and a possible lawsuit.

Biocryst plunges Biocryst plunges

6:50 a.m. yesterday

Premium Lock Bob Ingram is new chair at Novan; Neal Hunter steps down

Novan Therapeutics Novan Therapeutics, a high-profile emerging pharmaceutical firm backed by big-name investors in the Triangle with a focus on developing new dermatology treatments, has a new chairman. But his name is a familiar one. Another well-known name leaves the board in the shuffle.

Updated 6:25 a.m. yesterday

Pozen name disappears after merger is closed

Pozen The name Pozen has disappeared following the closing of the merger between the Chapel Hill-based pharmaceutical firm and Canada-based Tribute.

6:19 a.m. yesterday

Twitter vs terror; diabetes cure?; McKinney's loss; LinkedIn plunge; Merck earnings

Bulldog In today's Bulldog wrapup of technology and life science news: Twitter cracks down on terror; J&J pursues diabetes cure; McKinney loses major account; LinkedIn's shares plunge 44 percent; and Merck sales miss estimates.

Updated 2:46 p.m. Monday

Premium Lock Workforce expert: Healthcare jobs will change but the field remains 'hands on'

Healthcare workers are hardly immune from the threat of a jobless future as being explored in this week's Emerging Issues Forum "Future Work" conference. But as one of speakers explains opportunities will remain available for humans in healthcare.

Reg Javier Reg Javier

Updated 2:25 p.m. Monday

CED picks 50-plus emerging startups to present at Life Science Conference

CED Life Science Conference 2016 More than 50 emerging life science startups will have the chance to make their case for investment to possible backers at the CED's Life Science Conference next month. The CED announced its selections early Monday.

2:16 p.m. Monday

WTW news in review: Week of Feb. 1, part two

Week in review Here's a look back at technology, life science and other related news as reported in WRAL TechWire for the week of Feb. 1, part two of two:

2:10 p.m. Monday

WTW news in review: Week of Feb. 1, part one

Week in review Here's a look back at technology, life science and other related news as reported in WRAL TechWire for the week of Feb. 1, part one of two.

2:07 p.m. Monday

WTW wants you involved: Send your news - and your opinions

Contribute to WRALTechWire WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.

Updated February 5

$43B Syngenta sale to ChemChina could benefit North Carolina

"ChemChina has demonstrated a strategic and pragmatic approach with other investments the company has made in U.S. operations," says N.C. Biotechnology Center exec. "We expect that as a result, it will continue to value the advantages provided within North Carolina, as the largest cluster of high-tech agriculture in the world."

Syngenta's new lab in RTP Syngenta's new lab in RTP

Updated February 5

NC Biotechnology Center awards $1.6M in grants, loans

Biotech     ‚ÄčThe North Carolina Biotechnology Center awarded more than $1.63 million in 18 loans and grants to propel the life science sector statewide during the last quarter of 2015. Among the total is almost $600,000 awarded through the new Biotechnology Innovation Grant program.

February 4

Quintiles exec on immunotherapy: 'It's working'

Cancer research  In observance of Feb. 4 as "World Cancer Day," Terry Murdock, the head of the Oncology Center of Excellence at Quintiles, writes in a blog that "there is much to celebrate" this year in the fight against cancer.

February 3

Premium Lock FDA trial 'hold' triggers 25% dive in Heat Bio stock

Heat Biologics Shares in Heat Biologics plunged 25 percent Wednesday after the company disclosed that the FDA put a "partial clinical hold" on a recently launched clinical trial. However, Heat says its "timelines" for the treatment "remain materially unchanged."

Updated February 3

GSK posts $616M loss for 4th quarter; CEO sees 'substantial progress'

GSK in Zebulon  British-based drugmaker GlaxoSmithKline (NYSE: GSK) posted a loss of $616 million for the fourth quarter of 2015 - compared with a profit of over $1 for the same period a year earlier- as the company moved to integrate new businesses. Its top exec says GSK is making progress.

Updated February 3

Syngenta, which has big RTP presence, is being sold for $43B

After saying "no" to a $46.5 billion bid from Monsanto, the board of crop giant Syngenta has said "yes" to a $43 billion acquisition by Chinese chemical giant ChemChina. Syngenta has a big presence in RTP.

Architectural rendering of Syngenta expansion Architectural rendering of Syngenta expansion

February 2

Premium Lock GSK expands cancer drug development deal with Adaptimmune

Cancer research  GlaxoSmithKline, which sold its oncology portfolio to Novartis in 2014, is expanding a development deal with Adaptimmune to explore possible cancer treatments. GSK announces earnings on Wednesday.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith